phf8 Antibody

What is PHF8 and why is it important in epigenetic research?

PHF8 is a histone lysine demethylase that belongs to the family of JmjC domain-containing proteins. It is encoded by the PHF8 gene in humans and may also be known as JHDM1F, KDM7B, MRXSSD, or ZNF422. Structurally, PHF8 is a protein with a molecular mass of approximately 117.9 kilodaltons . PHF8 serves as a critical epigenetic regulator through its demethylase activity, primarily targeting histone marks including H4K20me1 (histone H4 lysine 20 monomethylation), H3K9me1/2 (histone H3 lysine 9 mono/dimethylation), and H3K27me2 (histone H3 lysine 27 dimethylation) . The protein contains a PHD finger domain that specifically recognizes and binds to H3K4me2/3 (histone H3 lysine 4 di/trimethylation) marks, which facilitates its recruitment to transcriptionally active regions of chromatin . This dual functionality of substrate recognition and demethylation positions PHF8 as a key player in chromatin-based gene regulation, cell cycle progression, and potentially cancer development.

What are the common applications for PHF8 antibodies in research?

PHF8 antibodies are utilized across numerous experimental techniques in epigenetic and molecular biology research. The primary applications include:

• Western Blotting (WB): For detecting and quantifying PHF8 protein levels in cell lysates and tissue samples, providing information about protein expression in different conditions.

• Immunohistochemistry (IHC): Both paraffin-embedded (IHC-p) and frozen sections can be analyzed to visualize PHF8 localization in tissues, which is particularly useful for studies involving developmental biology or disease pathology.

• Immunocytochemistry (ICC): To examine subcellular localization of PHF8 in cultured cells, particularly its nuclear distribution pattern.

• Immunoprecipitation (IP): Used to isolate PHF8 and its interacting partners, critical for studying protein-protein interactions.

• Chromatin Immunoprecipitation (ChIP): For mapping PHF8 binding sites across the genome, especially at promoter regions, which is essential for understanding its role in transcriptional regulation .

• ChIP-sequencing (ChIP-seq): Provides genome-wide mapping of PHF8 binding sites, revealing its distribution relative to transcription start sites and association with specific histone marks .

The choice of application influences which PHF8 antibody product is most suitable, as antibodies often show application-specific performance characteristics .

What validation methods should be used to confirm PHF8 antibody specificity?

When validating PHF8 antibodies for research applications, multiple complementary approaches should be employed:

• siRNA-mediated knockdown: Compare antibody signals between control and PHF8-depleted samples. An authentic PHF8 antibody will show significantly reduced signal in knockdown conditions. Studies have demonstrated that PHF8-specific siRNA transfection leads to increased H4K20me1 levels, providing an indirect confirmation of antibody specificity .

• Overexpression controls: Comparing signals in cells overexpressing wild-type PHF8 versus catalytically inactive mutants (such as PHF8 H247A) or domain deletion mutants (PHF8ΔPHD) can verify antibody specificity and provide insights into functional domains .

• Peptide competition assays: Pre-incubating the antibody with excess PHF8 peptide should abolish specific signals if the antibody is truly recognizing PHF8.

• Western blot analysis: Confirm the antibody detects a protein of the expected molecular weight (~118 kDa) in appropriate cellular contexts.

• Immunoprecipitation followed by mass spectrometry: This approach identifies if the antibody specifically pulls down PHF8 and its known interaction partners.

• Cross-species reactivity testing: Test antibody performance across species if orthologs study is intended, as PHF8 has orthologs in canine, porcine, monkey, mouse and rat models .

How do cell cycle stages affect PHF8 chromatin association and enzymatic activity?

PHF8 exhibits dynamic associations with chromatin throughout the cell cycle, which has significant implications for experimental design when studying this protein:

• G1 phase: PHF8 predominantly binds to promoter regions (~77% of binding sites), where it contributes to transcriptional activation of genes required for cell cycle progression .

• G1/S transition: As cells approach S phase, PHF8 binding increases at promoters of G1/S transition-regulated genes. Additionally, approximately 13,000 new PHF8 binding sites appear, mostly at intra- or extra-genic loci (>70%), suggesting broader regulatory roles .

• Mitosis: PHF8 dissociates from chromatin during prophase, coinciding with an increase in H4K20me1 levels and Pr-Set7 (the methyltransferase for H4K20me1). This dissociation becomes more pronounced as chromosomes condense, and PHF8 reassociates with chromatin during telophase .

This cell cycle-dependent regulation has functional consequences:

• PHF8 depletion leads to delayed G1/S transition

• Cells treated with PHF8 siRNA show decreased proliferation

• Loss of PHF8 results in decreased cell size

A data table summarizing these cell cycle-dependent changes in PHF8 activity:

This dynamic association pattern must be considered when designing ChIP experiments or when interpreting immunofluorescence data for PHF8 localization studies .

What are the functional interactions between PHF8 and other transcriptional regulators?

PHF8 operates within a complex network of transcriptional regulators, and understanding these interactions is crucial for comprehensive studies:

• E2F1 interaction: PHF8 physically associates with E2F1, a critical G1/S transition regulator. ChIP-seq analysis reveals that >79% of E2F1-bound promoters correspond to those binding PHF8, suggesting a coordinated role in cell cycle regulation .

• HCF-1 interaction: PHF8 co-immunoprecipitates with HCF-1 (Host Cell Factor 1), with the interaction mapped to the N-terminus of HCF-1, a region essential for G1/S transition regulation. PHF8 knockdown impairs HCF-1 recruitment to target promoters, while HCF-1 knockdown does not affect PHF8 recruitment, suggesting PHF8 functions upstream of HCF-1 .

• Set1A interaction: Set1A, a histone methyltransferase responsible for H3K4 methylation, interacts with PHF8. This interaction potentially creates a feedback loop where PHF8 is recruited to H3K4me2/3 sites through its PHD finger, while also facilitating Set1A recruitment to maintain these marks .

• YY1 interaction: PHF8 physically interacts with YY1 (Yin Yang 1), a transcription factor. Approximately 44% of YY1 chromatin binding sites are co-occupied by PHF8, and they predominantly co-localize at gene promoter regions. PHF8 demethylates YY1 at lysine 258, affecting YY1 K258me2/3 levels .

• L3MBTL1 displacement: PHF8-mediated demethylation of H4K20me1 appears to displace L3MBTL1, a known repressor that binds H4K20me1, from promoters. This displacement mechanism potentially contributes to gene activation during cell cycle progression .

These interactions position PHF8 as a central node in coordinating histone demethylation with transcription factor activity and other chromatin modifications, particularly during cell cycle progression.

What are the technical challenges in studying PHF8 demethylase activity in vitro and in vivo?

Researchers face several significant challenges when investigating PHF8 demethylase activity:

• Substrate specificity determination: PHF8 targets multiple histone marks (H4K20me1, H3K9me1/2, H3K27me2), and this specificity may vary by:

  • Cell type: Studies show different substrate preferences in HeLa versus U2OS cells

  • Chromatin context: The local histone modification environment affects PHF8 activity

  • Protein domains: The PHD finger is required for some but not all demethylation activities

• Redundancy with other demethylases: Other H3K9/K27 demethylases may compensate for PHF8 loss, minimizing siRNA effects on certain substrates. This makes it difficult to isolate PHF8-specific contributions .

• Cell cycle variations: PHF8 activity and substrate preference change throughout the cell cycle, requiring careful synchronization protocols for consistent results .

• Recombinant protein production challenges: Production of enzymatically active PHF8 requires proper folding and may necessitate eukaryotic expression systems rather than bacterial systems.

• Assay conditions for in vitro activity: Buffer conditions, cofactor requirements (Fe(II), α-ketoglutarate), and appropriate substrate presentation (peptides vs. nucleosomes) significantly impact enzymatic activity measurements.

• In vivo validation: Confirming activity in cellular contexts requires combinations of:

  • ChIP-seq before and after PHF8 depletion

  • Immunofluorescence with quantitative image analysis

  • Biochemical fractionation to isolate chromatin-bound PHF8

  • Use of catalytically dead mutants (H247A) as controls

• Non-histone substrates: Recent evidence suggests PHF8 can demethylate non-histone proteins like YY1 at K258, requiring additional methodological approaches beyond histone-focused assays .

Researchers have addressed these challenges through comprehensive experimental designs that include multiple substrate analysis, domain deletion studies, and comparative analyses across cell types and cell cycle stages.

How is PHF8 dysregulation implicated in cancer and other diseases?

The role of PHF8 in disease pathogenesis is increasingly recognized, with particular emphasis on cancer development:

• Cell proliferation regulation: PHF8 functions as a cell cycle regulator, particularly at the G1/S transition. PHF8 depletion leads to decreased cell proliferation and delayed S phase entry, suggesting its potential oncogenic role in promoting cancer cell proliferation .

• PHF8/YY1 axis in cancer: Recent research indicates that targeting the PHF8/YY1 axis can suppress cancer cell growth. PHF8 interacts with YY1 (a transcription factor) and co-localizes at gene promoters, potentially regulating cancer-associated genes .

• Demethylase inhibition as therapy: Small molecule inhibitors of PHF8 (such as "iPHF8") have shown potent inhibitory effects on PHF8 activity (IC50= 2.01 μM), suggesting potential therapeutic applications .

• X-linked intellectual disability: Mutations in PHF8 have been associated with X-linked intellectual disability with cleft lip/palate (XLID), indicating its importance in neurodevelopment. The gene is also referred to as MRXSSD (Mental Retardation, X-linked, with Syndromic Short stature and Distinct facial appearance) .

• Epigenetic dysregulation: As PHF8 regulates histone methylation states, its dysfunction can lead to aberrant gene expression patterns. Its preferential association with H3K4me2/3-positive promoters suggests it primarily affects actively transcribed genes, with potential widespread consequences when dysregulated .

Understanding the mechanistic details of PHF8 in disease contexts offers opportunities for diagnostic and therapeutic development, particularly in oncology and developmental disorders.

What techniques are most effective for studying PHF8-associated chromatin modifications?

For comprehensive analysis of PHF8-associated chromatin modifications, researchers should consider a multi-modal approach:

• ChIP-sequencing (ChIP-seq): This technique provides genome-wide mapping of PHF8 binding sites and associated histone modifications. The search results indicate PHF8 tags distribution relative to transcription start sites corresponds to H3K4me2 mark distribution, suggesting a functional relationship . When performing PHF8 ChIP-seq:

  • Use synchronized cell populations to account for cell cycle variation

  • Include controls for antibody specificity (PHF8 knockdown samples)

  • Consider dual ChIP-seq for PHF8 and its substrate marks (H4K20me1, H3K9me1/2)

• Sequential ChIP (Re-ChIP): This approach can determine if PHF8 and its interaction partners (E2F1, HCF-1, YY1) simultaneously occupy the same genomic regions, providing insight into functional complexes .

• Immunofluorescence microscopy with quantitative image analysis:

  • Pre-extraction protocols reveal chromatin-bound PHF8 fraction

  • Cell cycle synchronization enables temporal analysis

  • Comparison of wild-type vs. mutant PHF8 (H247A) effects on histone mark levels

• Biochemical fractionation combined with Western blotting: Isolating chromatin-bound fractions from cells at different cell cycle stages reveals dynamic changes in PHF8 association and corresponding histone mark levels .

• In vitro demethylation assays: These assays directly measure PHF8 enzymatic activity on various substrates:

  • Peptide substrates for initial activity screening

  • Mononucleosomes for more physiological context

  • Comparison of different domains (full-length vs. ΔPHD) to understand contribution of each domain

• Mass spectrometry analysis: For unbiased identification of histone modifications affected by PHF8 activity or for identifying non-histone substrates, such as the YY1 K258 demethylation .

A combined approach using these techniques provides complementary data on PHF8 function, substrate specificity, and regulatory mechanisms.

How can antibody-based approaches be optimized for studying PHF8 protein-protein interactions?

Studying PHF8 protein-protein interactions requires carefully optimized antibody-based approaches:

• Co-immunoprecipitation optimization:

  • Use of different extraction buffers to preserve specific interactions while minimizing background

  • Nuclear extraction protocols are critical as PHF8 is primarily nuclear

  • Crosslinking approaches (formaldehyde or DSP) to capture transient interactions

  • Native vs. denatured conditions depending on interaction stability

PHF8 has been successfully co-immunoprecipitated with E2F1, HCF-1, Set1A, and YY1 using optimized protocols .

• Proximity ligation assay (PLA):

  • Allows visualization of protein-protein interactions in situ

  • Provides spatial information about where in the nucleus PHF8 interactions occur

  • Requires careful antibody validation to minimize false positives

• Bimolecular Fluorescence Complementation (BiFC):

  • Can confirm direct interactions in living cells

  • Useful for mapping interaction domains by testing truncated constructs

• Pull-down assays with recombinant proteins:

  • Direct interaction between purified PHF8 and YY1 has been demonstrated in vitro

  • PHD finger of PHF8 specifically binds to H3K4me2/3 histone tails

  • Domain-mapping studies can identify critical interaction regions

• Gel filtration chromatography:

  • Has revealed co-fractionation of native PHF8, E2F1, HCF-1 and Set1A

  • Provides evidence for stable complex formation

• Chromatin interaction analysis:

  • ChIP-seq analysis has shown PHF8 and YY1 co-localization, with approximately 44% of YY1 chromatin binding sites co-occupied by PHF8

  • PHF8 and E2F1 show significant overlap (>79% of E2F1-bound promoters correspond to PHF8-bound promoters)

When implementing these approaches, researchers should:

• Validate antibody specificity in the specific experimental condition

• Include appropriate controls (IgG, isotype controls)

• Consider cell cycle stage, as PHF8 interactions may be cell cycle-dependent

• Use multiple complementary approaches to confirm interactions

What are the emerging applications of PHF8 antibodies in single-cell epigenetic analysis?

Single-cell epigenetic analysis represents a frontier in understanding PHF8 function with cellular heterogeneity:

• Single-cell ChIP-seq adaptations:

  • Traditional ChIP-seq requires millions of cells, but emerging single-cell adaptations allow exploration of PHF8 binding heterogeneity within populations

  • Can reveal if PHF8 acts differently in subpopulations of cells (e.g., cells at different cell cycle stages)

  • Particularly valuable given PHF8's cell cycle-dependent activity

• CUT&Tag and CUT&RUN at single-cell level:

  • These techniques offer higher sensitivity than traditional ChIP

  • More amenable to low-input and single-cell applications

  • Can be multiplexed to simultaneously analyze PHF8 and its substrate modifications

• Imaging-based approaches:

  • Combining immunofluorescence for PHF8 with FISH for target genes

  • Super-resolution microscopy to visualize PHF8 distribution at sub-nuclear level

  • Live-cell imaging with tagged PHF8 to track dynamic changes during cell cycle progression

• Single-cell multi-omics integration:

  • Combining scCUT&Tag for PHF8 with scRNA-seq to correlate binding with transcriptional output

  • Integrating chromatin accessibility data to understand how PHF8 influences chromatin structure

• Mass cytometry applications:

  • CyTOF approaches using metal-conjugated antibodies against PHF8 and histone marks

  • Enables quantitative analysis of PHF8 levels alongside dozens of other proteins/modifications

These emerging applications will likely provide unprecedented insight into how PHF8 activity varies between individual cells and how this contributes to cellular heterogeneity in development and disease.

How do PHF8's distinct substrate specificities influence experimental design?

PHF8 exhibits complex substrate specificities that significantly impact experimental design:

• Histone substrate hierarchy:

  • PHF8 can demethylate H4K20me1, H3K9me1/2, and H3K27me2, but with different efficiencies

  • ChIP-seq analysis reveals PHF8 binding correlates primarily with H3K4me2/3 marks (via its PHD finger domain)

  • H4K20me1 appears to be a preferential substrate in many contexts, with significant increases observed upon PHF8 knockdown

• Context-dependent activity:

  • The local chromatin environment influences substrate selection

  • PHF8 requires its PHD finger to efficiently demethylate H4K20me1 or H3K9me1 on nucleosomes, but not for H3K9me2 and H3K27me2

  • This necessitates using appropriate substrates (mononucleosomes vs. peptides) in in vitro assays

• Cell type variation:

  • In HeLa cells, PHF8 overexpression primarily affects H4K20me1

  • In U2OS cells, it affects both H4K20me1 (~20%) and H3K9me2 (~60%)

  • This requires careful consideration of cell type selection for experiments

• Cell cycle dependence:

  • PHF8 activity changes throughout the cell cycle

  • H4K20me1 levels are inversely correlated with PHF8 chromatin association

  • Experimental designs must include cell synchronization protocols when studying specific phases

• Non-histone substrates:

  • PHF8 can demethylate non-histone proteins like YY1 at K258

  • This requires specialized antibodies for detecting methylation states of specific residues

A comparison table of PHF8 substrate specificities:

These substrate specificities necessitate multi-faceted experimental approaches, including:

• Analysis of multiple histone marks simultaneously

• Use of domain mutants to dissect functionality

• Cell type-specific validation

• Cell cycle synchronization protocols

What considerations are important when developing inhibitors targeting PHF8 demethylase activity?

The development of PHF8 inhibitors represents an emerging therapeutic strategy with several important considerations:

• Structural basis for inhibitor design:

  • PHF8 contains a catalytic JmjC domain that requires Fe(II) and α-ketoglutarate as cofactors

  • Inhibitors may target the catalytic site directly or allosterically modify enzyme activity

  • Crystal structures of PHF8 bound to substrates provide valuable information for structure-based drug design

• Inhibitor specificity challenges:

  • JmjC domain is conserved across many histone demethylases

  • Achieving selectivity for PHF8 over related enzymes requires targeting unique structural features

  • iPHF8 has demonstrated potent inhibitory effects on PHF8 activity with an IC50 of 2.01 μM

• Validation of inhibitor activity:

  • Monitor changes in histone mark levels (particularly H4K20me1 and H3K9me1/2)

  • Assess effects on PHF8-regulated gene expression

  • Evaluate cell cycle progression, as PHF8 regulates G1/S transition

  • Test for displacement of PHF8 from chromatin

• Functional consequences:

  • PHF8 inhibition may affect cell proliferation, as PHF8 knockdown decreases proliferation

  • May influence specific cancer types where PHF8 activity is elevated

  • Could impact the PHF8/YY1 axis implicated in cancer cell growth

• Translational considerations:

  • Cell-type specific effects must be evaluated

  • Potential compensatory mechanisms through related demethylases

  • Therapeutic window between cancer efficacy and normal cell toxicity

  • Delivery methods to target nuclear localized PHF8

• Combination approaches:

  • PHF8 inhibitors may synergize with other epigenetic therapies

  • Combination with cell cycle inhibitors could enhance anti-proliferative effects

  • Targeting multiple nodes in the PHF8-containing complex (e.g., PHF8/YY1 axis) may increase efficacy

The development of PHF8 inhibitors represents a promising research direction with potential therapeutic applications, particularly in cancer contexts where PHF8 activity may contribute to disease progression.